Hillevax, INC Form 4 insider transactions

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. have sold their entire 6,724,000 shares of HilleVax, Inc. common stock for $1.95 per share as part of a tender offer by XOMA Royalty Corporation.

Frazier Life Sciences X, L.P. and Patrick J. Heron disposed of HilleVax, Inc. common stock and restricted stock units following the company's merger with XRA 4 Corp. for $1.95 cash and a CVR per share.

HilleVax, Inc. President and CEO, Robert Hershberg, reported the disposition of all his common stock holdings following the company's acquisition by XOMA Royalty Corporation.

HilleVax Director Nanette Cocero reported the disposition of common stock and vested RSUs following the company's merger with XOMA Royalty Corporation.

HilleVax, Inc. became a wholly-owned subsidiary of XOMA Royalty Corporation following a tender offer and merger, with shareholders receiving $1.95 cash and one CVR per share.

HilleVax Director Shelley Chu reported the disposition of 17,199 common shares following the company's merger with XOMA Royalty Corporation.

HilleVax Director Gary Dubin reported the disposition of 17,199 common shares following the company's merger into a wholly-owned subsidiary of XOMA Royalty Corporation.

HilleVax Director Aditya Kohli reports disposition of shares and restricted stock units following the company's merger with XOMA Royalty Corporation.

Julie Gerberding, a director at HilleVax, Inc., reported the disposition of all her common stock holdings following the company's acquisition by XOMA Royalty Corporation.

HilleVax's Chief Financial Officer, Shane Maltbie, disposed of all his common stock holdings following the company's acquisition by XOMA Royalty Corporation.

HilleVax Director Jaime Sepulveda disposed of all common stock holdings following the company's acquisition by XOMA Royalty Corporation.

HilleVax, Inc. Director Patrick J. Heron was granted 17,199 Restricted Stock Units as part of the company's non-employee director compensation program, further aligning his interests with shareholders.

HilleVax, Inc. Director Aditya Kohli reported the acquisition of 17,199 Restricted Stock Units (RSUs) as part of the company's non-employee director compensation program, alongside the cancellation of 83,906 unvested RSUs following a prior termination of employment.

HilleVax, Inc. Director Shelley Chu was granted 17,199 Restricted Stock Units (RSUs) on June 23, 2025, as part of the company's non-employee director compensation program.

HilleVax, Inc. Director Jaime Sepulveda was granted 17,199 Restricted Stock Units (RSUs) as part of the company's non-employee director compensation program, vesting over one year or upon a change in control.

HilleVax, Inc. Director Nanette Cocero was granted 17,199 Restricted Stock Units (RSUs) as part of the company's Non-Employee Director Compensation Program, as disclosed in a recent SEC Form 4 filing.

HilleVax, Inc. Director Julie L. Gerberding was granted 17,199 Restricted Stock Units (RSUs) as part of the company's Non-Employee Director Compensation Program.

HilleVax, Inc. Director Gary Dubin was granted 17,199 Restricted Stock Units (RSUs) on June 23, 2025, as part of the company's non-employee director compensation program.

HilleVax, Inc. Director Jeryl L. Hilleman was granted 17,199 Restricted Stock Units (RSUs) as part of the company's non-employee director compensation program.

Director Shelley Chu reports the acquisition of stock options in HilleVax, Inc. pursuant to the non-employee director compensation program.

Director Nanette Cocero acquired 22,500 stock options in HilleVax, Inc. on June 6, 2024, as part of the non-employee director compensation program.

Julie Gerberding, a director of HilleVax, Inc., acquired 22,500 stock options on June 6, 2024, as part of the company's non-employee director compensation program.

Director Jeryl L Hilleman acquired 22,500 stock options in HilleVax, Inc. on June 6, 2024, according to a Form 4 filing with the SEC.

Jaime Sepulveda, a director of HilleVax, Inc., was granted stock options for 22,500 shares on June 6, 2024.

Director Patrick J. Heron reports the acquisition of stock options in HilleVax, Inc. pursuant to the company's non-employee director compensation program.

HilleVax CEO Robert Hershberg sold shares of common stock to cover tax withholding obligations related to the settlement of restricted stock units.

HilleVax's Chief Financial Officer, Shane Maltbie, sold shares of common stock to satisfy tax withholding obligations related to the settlement of restricted stock units.

Frazier Life Sciences X, L.P. files an amended Form 4 to correct an error in a previous filing regarding the purchase of HilleVax, Inc. (HLVX) common stock.

Director Aditya Kohli of HilleVax, Inc. executed sales of common stock totaling 18,000 shares between May 20 and May 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Aditya Kohli of HilleVax, Inc. executed sales of common stock between May 1 and May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.